Murali has a deep passion for transforming Science, Technology and Medicine at scale to impact patient lives. Murali joined Danaher (NYSE: DHR) in 2019, a global Science and Technology leader with $32.5 Billion in revenue and >$180 Billion market cap, operating companies including Beckman Coulter, Leica Micro- and Biosystems, IDT, Sciex, Aldevron, Cytiva and more. As Head of Danaher Ventures, Murali’s team supports Danaher’s strategy and investments across healthcare and are responsible for an active portfolio of over 40 companies valued at >$11 Billion. Murali serves as a Board Director for more than five companies and has joint responsibilities across Mergers & Acquisitions, including supporting previously the acquisition of
Aldevron. Prior to joining Danaher, Murali was Director of Business Development at Lam Research (NASDAQ: LRCX), a leader in Semiconductor manufacturing tools and responsible for Lam’s strategy and investments in Life Sciences. Murali had previously spent ~7 years at Illumina (NASDAQ: ILMN) as a Scientist, Inventor and Senior Manager, across Advanced Research, Technology Development and Product Development, leading technology teams that enabled the $1000 and $100 genomes. These products have generated over $4B in revenue for Illumina. Murali holds a Ph.D. in Electrical & Computer Engineering from the University of Illinois at Urbana-Champaign and is a graduate of the Stanford Executive Program. He is an inventor on 20 patents and has published in various scientific journals including Nature Nanotechnology, Nature Scientific Reports, Advanced Materials and Lab on Chip with >3000 citations. Murali also holds Bachelor of Science and Bachelor of Engineering degrees in Pure Mathematics, Computer Science and Electrical Engineering from University of Western Australia.
Murali has a deep passion for transforming Science, Technology and Medicine at scale to impact patient lives. Murali joined Danaher (NYSE: DHR) in 2019, a global Science and Technology leader with $32.5 Billion in revenue and >$180 Billion market cap, operating companies including Beckman Coulter, Leica Micro- and Biosystems, IDT, Sciex, Aldevron, Cytiva and more. As Head of Danaher Ventures, Murali’s team supports Danaher’s strategy and investments across healthcare and are responsible for an active portfolio of over 40 companies valued at >$11 Billion. Murali serves as a Board Director for more than five companies and has joint responsibilities across Mergers & Acquisitions, including supporting previously the acquisition of
Aldevron. Prior to joining Danaher, Murali was Director of Business Development at Lam Research (NASDAQ: LRCX), a leader in Semiconductor manufacturing tools and responsible for Lam’s strategy and investments in Life Sciences. Murali had previously spent ~7 years at Illumina (NASDAQ: ILMN) as a Scientist, Inventor and Senior Manager, across Advanced Research, Technology Development and Product Development, leading technology teams that enabled the $1000 and $100 genomes. These products have generated over $4B in revenue for Illumina. Murali holds a Ph.D. in Electrical & Computer Engineering from the University of Illinois at Urbana-Champaign and is a graduate of the Stanford Executive Program. He is an inventor on 20 patents and has published in various scientific journals including Nature Nanotechnology, Nature Scientific Reports, Advanced Materials and Lab on Chip with >3000 citations. Murali also holds Bachelor of Science and Bachelor of Engineering degrees in Pure Mathematics, Computer Science and Electrical Engineering from University of Western Australia.
Murali has a deep passion for transforming Science, Technology and Medicine at scale to impact patient lives. Murali joined Danaher (NYSE: DHR) in 2019, a global Science and Technology leader with $32.5 Billion in revenue and >$180 Billion market cap, operating companies including Beckman Coulter, Leica Micro- and Biosystems, IDT, Sciex, Aldevron, Cytiva and more. As Head of Danaher Ventures, Murali’s team supports Danaher’s strategy and investments across healthcare and are responsible for an active portfolio of over 40 companies valued at >$11 Billion. Murali serves as a Board Director for more than five companies and has joint responsibilities across Mergers & Acquisitions, including supporting previously the acquisition of
Aldevron. Prior to joining Danaher, Murali was Director of Business Development at Lam Research (NASDAQ: LRCX), a leader in Semiconductor manufacturing tools and responsible for Lam’s strategy and investments in Life Sciences. Murali had previously spent ~7 years at Illumina (NASDAQ: ILMN) as a Scientist, Inventor and Senior Manager, across Advanced Research, Technology Development and Product Development, leading technology teams that enabled the $1000 and $100 genomes. These products have generated over $4B in revenue for Illumina. Murali holds a Ph.D. in Electrical & Computer Engineering from the University of Illinois at Urbana-Champaign and is a graduate of the Stanford Executive Program. He is an inventor on 20 patents and has published in various scientific journals including Nature Nanotechnology, Nature Scientific Reports, Advanced Materials and Lab on Chip with >3000 citations. Murali also holds Bachelor of Science and Bachelor of Engineering degrees in Pure Mathematics, Computer Science and Electrical Engineering from University of Western Australia.